Ontology highlight
ABSTRACT: Background
PEP02 (also known as MM-398, nal-IRI) is a novel nanoparticle formulation of irinotecan encapsulated in liposomes. The aims of this study were to investigate the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and pharmacokinetics (PK) of PEP02 in combination with 5-FU and LV, in patients with advanced refractory solid tumors.Methods
Patients were enrolled in cohorts to receive PEP02 from 60 to 120 mg/m2 (dose expressed as the irinotecan hydrochloride trihydrate salt) as a 90-min intravenous infusion on day 1, followed by 24 h infusion of 5-FU 2,000 mg/m2 and LV 200 mg/m2 on days 1 and 8, every 3 weeks.Results
A total of 16 patients were assigned to four dose levels, 60 (three patients), 80 (six patients), 100 (
SUBMITTER: Chiang NJ
PROVIDER: S-EPMC5117585 | biostudies-literature | 2016 Nov
REPOSITORIES: biostudies-literature